Neurotech International Ltd
Company Profile
Business description
Neurotech International Ltd is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), along with Rett Syndrome.
Contact
55 Collins Street
Suite 102, Level 1
MelbourneVIC3000
AUST: +61 394983132
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
18
Stocks News & Analysis
stocks
Overvalued ASX share has overly ambitious profit target
stocks
7 undervalued US stocks that crushed earnings
stocks
Undervalued ASX share hitting on all cylinders
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,997.30 | 168.10 | -1.83% |
| CAC 40 | 8,216.78 | 135.22 | -1.62% |
| DAX 40 | 26,045.37 | 553.27 | -2.08% |
| Dow JONES (US) | 50,985.88 | 622.29 | -1.21% |
| FTSE 100 | 10,689.87 | 191.68 | -1.76% |
| HKSE | 23,508.17 | 245.67 | -1.03% |
| NASDAQ | 24,329.13 | 180.63 | -0.74% |
| Nikkei 225 | 58,860.43 | 801.59 | -1.34% |
| NZX 50 Index | 14,306.96 | 3.19 | 0.02% |
| S&P 500 | 7,357.05 | 59.54 | -0.80% |
| S&P/ASX 200 | 8,883.20 | 161.50 | -1.79% |
| SSE Composite Index | 3,584.58 | 17.99 | -0.50% |